Imatinib for chronic myeloid leukaemia: a NICE mess.
Rajaratnam
G
G
Edwards
J
J
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001549:Benzamides; D003362:Cost-Benefit Analysis; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009313:National Health Programs / Q000191:economics*; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome; D006113:United Kingdom
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate